MovDisordV3, PascalFrancis, Checkpoint, bibRecord, 002D25

SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia

Identifieur interne : 002D25 ( PascalFrancis/Checkpoint ); précédent : 002D24; suivant : 002D26

SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia

Auteurs : D. Mathen [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni]

Source :

Movement disorders [ 0885-3185 ] ; 1999.

RBID : Pascal:99-0475677

Descripteurs français

Pascal (Inist)
- Dystonie, Dopamine, Lévodopa, Fluoxétine, Antidépresseur, Venlafaxine, Etude cas, Traitement, Toxicité, Homme, Inhibiteur recapture, Sérotonine, Phényléthylamine dérivé.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antidepressant agent, Case study, Dopamine, Dystonia, Fluoxetine, Human, Levodopa, Reuptake inhibitor, Serotonin, Toxicity, Treatment, Venlafaxine.

Affiliations:

Royaume-Uni

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 002D45
to stream PascalFrancis, to step Curation: 003A79

Links to Exploration step

Pascal:99-0475677

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia</title>
<author><name sortKey="Mathen, D" sort="Mathen, D" uniqKey="Mathen D" first="D." last="Mathen">D. Mathen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bhatia, K P" sort="Bhatia, K P" uniqKey="Bhatia K" first="K. P." last="Bhatia">K. P. Bhatia</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0475677</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0475677 INIST</idno>
<idno type="RBID">Pascal:99-0475677</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002D45</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003A79</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002D25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia</title>
<author><name sortKey="Mathen, D" sort="Mathen, D" uniqKey="Mathen D" first="D." last="Mathen">D. Mathen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bhatia, K P" sort="Bhatia, K P" uniqKey="Bhatia K" first="K. P." last="Bhatia">K. P. Bhatia</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressant agent</term>
<term>Case study</term>
<term>Dopamine</term>
<term>Dystonia</term>
<term>Fluoxetine</term>
<term>Human</term>
<term>Levodopa</term>
<term>Reuptake inhibitor</term>
<term>Serotonin</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Venlafaxine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dystonie</term>
<term>Dopamine</term>
<term>Lévodopa</term>
<term>Fluoxétine</term>
<term>Antidépresseur</term>
<term>Venlafaxine</term>
<term>Etude cas</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Homme</term>
<term>Inhibiteur recapture</term>
<term>Sérotonine</term>
<term>Phényléthylamine dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>14</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MATHEN (D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MARSDEN (C. D.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BHATIA (K. P.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square London</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>874-876</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000089971250280</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0475677</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Distonía</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Fluoxétine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Fluoxetine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Fluoxetina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antidépresseur</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antidepressant agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antidepresor</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Venlafaxine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Venlafaxine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Venlafaxina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Case study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Inhibiteur recapture</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Reuptake inhibitor</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Inhibidor recaptura</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Sérotonine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Serotonin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Serotonina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Phényléthylamine dérivé</s0>
<s4>INC</s4>
<s5>93</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Muscle strié pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fN21><s1>305</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Mathen, D" sort="Mathen, D" uniqKey="Mathen D" first="D." last="Mathen">D. Mathen</name>
</noRegion>
<name sortKey="Bhatia, K P" sort="Bhatia, K P" uniqKey="Bhatia K" first="K. P." last="Bhatia">K. P. Bhatia</name>
<name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D25 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 002D25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:99-0475677
   |texte=   SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia

SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri